PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Good response of an aggressive rare variant of signet ring cell carcinoma of prostate with hormonal therapy.

Abstract Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity, characterised by its aggressive nature and dismal prognosis. We report a case of an advanced SRCC of the prostate presenting as a large pelvic mass with obstructive uropathy and rectal involvement managed by complete androgen blockade. At 24 months follow-up, the patient has no evidence of progression or metastasis. Aggressive management with multimodality approach combining surgery, radiation and hormonal ablation can result in long disease-free survival in some patients, despite the aggressive nature of this disease.
PMID
Related Publications

Signet-ring cell carcinoma of the breast with uterine metastasis treated with extensive cytoreductive surgery: a case report and brief review of the literature.

Signet ring cell carcinoma of the prostate successfully treated with endocrine therapy: a case report.

Signet ring cell carcinoma in the prostate.

Primary signet-ring cell carcinoma of the prostate.

Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade.

Authors

Mayor MeshTerms
Keywords
Journal Title bmj case reports
Publication Year Start




PMID- 28275015
OWN - NLM
STAT- MEDLINE
DA  - 20170309
DCOM- 20170316
LR  - 20170316
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2017
DP  - 2017 Mar 08
TI  - Good response of an aggressive rare variant of signet ring cell carcinoma of
      prostate with hormonal therapy.
LID - bcr2016217567 [pii]
LID - 10.1136/bcr-2016-217567 [doi]
AB  - Primary signet ring cell carcinoma (SRCC) of the prostate is a rare entity,
      characterised by its aggressive nature and dismal prognosis. We report a case of 
      an advanced SRCC of the prostate presenting as a large pelvic mass with
      obstructive uropathy and rectal involvement managed by complete androgen
      blockade. At 24 months follow-up, the patient has no evidence of progression or
      metastasis. Aggressive management with multimodality approach combining surgery, 
      radiation and hormonal ablation can result in long disease-free survival in some 
      patients, despite the aggressive nature of this disease.
CI  - 2017 BMJ Publishing Group Ltd.
FAU - Tiwari, Deviprasad
AU  - Tiwari D
AD  - All India Institute of Medical Sciences, New Delhi, India.
FAU - Nayak, Brusabhanu
AU  - Nayak B
AD  - All India Institute of Medical Sciences, New Delhi, India.
FAU - Seth, Amlesh
AU  - Seth A
AD  - All India Institute of Medical Sciences, New Delhi, India.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170308
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - Aged
MH  - Androgen Antagonists/*therapeutic use
MH  - Carcinoma, Signet Ring Cell/*drug therapy/surgery
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*drug therapy/surgery
MH  - Treatment Outcome
EDAT- 2017/03/10 06:00
MHDA- 2017/03/17 06:00
CRDT- 2017/03/10 06:00
AID - bcr-2016-217567 [pii]
AID - 10.1136/bcr-2016-217567 [doi]
PST - epublish
SO  - BMJ Case Rep. 2017 Mar 8;2017. pii: bcr2016217567. doi: 10.1136/bcr-2016-217567.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>